“ACTIV-6 is the only trial with a primary outcome of patient-reported sustained recovery and, in this trial of fluvoxamine 100 mg twice daily for 13 days, there was no evidence of benefit ...

To read this article for CME, click here. March 3, 2008 — Jazz Pharmaceuticals Inc has announced that it has received US Food and Drug Administration (FDA) approval for a once-daily extended ...

Fluvoxamine (Psyvoxin (50 mg)) is an antidepressant, prescribed for psychiatric disorders such as obsessive-compulsive disorder, social phobia and depression. It inhibits the uptake of serotonin ...